Medical Device Coating Mitigates Neutrophil Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for addressing inflammation and pain caused by foreign object placement, such as endotracheal tubes and catheters, are inadequate, leading to significant morbidity and mortality, with existing treatments failing to consistently provide relief from sore throat, tracheomalacia, and catheter-associated urinary tract infections.
Innovation Solution
A composition comprising N-Acetylcysteine and an aminoquinoline, potentially combined with an endonuclease, is administered or coated onto medical devices to mitigate neutrophil activation and inflammation by targeting Toll-Like Receptor 9 (TLR-9) and reducing reactive oxygen species production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If foreign objects such as endotracheal tubes and catheters are placed for standard medical care, then medical treatment function is provided, but local or systemic inflammatory response and tissue damage occur
Solution Approach 1:
The patent applies preliminary anti-action by pre-coating foreign objects with compositions containing TLR-9 antagonists and anti-inflammatory agents before insertion into the patient. This prevents neutrophil activation and inflammatory response before it can occur, addressing the harmful effects of foreign object placement while maintaining their medical treatment function.
Solution Approach 2:
The patent uses TLR-9 antagonists and anti-inflammatory agents as intermediary substances that mediate between the foreign object and the host immune system. These intermediaries block the harmful interaction between mitochondrial DNA released from injured cells and neutrophil TLR-9 receptors, preventing excessive inflammatory response while allowing the foreign object to perform its medical function.
2Reliability
If neutrophils are activated to respond to cellular injury, then immune defense is enhanced, but excessive reactive oxygen species production promotes tissue damage
Solution Approach 1:
The patent introduces anti-oxidant agents as intermediary substances that selectively modulate neutrophil function. These intermediaries allow neutrophils to maintain their immune defense capabilities while preventing excessive reactive oxygen species production that causes tissue damage. The anti-oxidants act as mediators between neutrophil activation and tissue protection.
Solution Approach 2:
The patent applies parameter changes by using agents that selectively alter specific parameters of neutrophil function - enhancing phagocytic activity and immune defense while simultaneously reducing reactive oxygen species production. This differential modulation of neutrophil parameters allows beneficial immune responses while minimizing harmful tissue damage.
3Reliability
If mitochondrial DNA is released from injured cells as an innate immune activator, then immune response is triggered, but it activates neutrophils causing sore throat and inflammation
Solution Approach 1:
The patent applies the taking out principle by specifically removing or blocking the harmful interaction between mitochondrial DNA and neutrophil TLR-9 receptors. The TLR-9 antagonist selectively extracts or removes the harmful signaling pathway activation while allowing other immune response mechanisms to function normally, thus preventing neutrophil-mediated inflammation without compromising overall immune defense.
Solution Approach 2:
The patent uses TLR-9 antagonists as intermediary substances that specifically block the mitochondrial DNA-neutrophil interaction. This intermediary prevents the harmful signaling cascade while allowing other immune pathways to remain functional, thus selectively preventing neutrophil activation and inflammation without abolishing the entire immune response.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The solution effectively decreases markers of neutrophil activation, inflammation, and tissue damage, providing relief from pain and infection associated with foreign object use by modulating immune responses and preventing further tissue injury.
Implementation Method 1
targeting Toll-Like Receptor 9 (TLR-9) and reducing reactive oxygen species production
Implementation Method 2
reducing reactive oxygen species production
Data Source
AI summary
Disclosed are compositions, medical devices and methods for ameliorating sterile injury due object use in a subject in need thereof. More particularly, the present disclosure relates to compositions including N-Acetylcysteine and an aminoquinoline. The present disclosure also relates to compositions including an endonuclease and an aminoquinoline. The present disclosure also relates to medical devices including a coating comprising N-Acetylcysteine, an aminoquinoline, an endonuclease, and combinations thereof.